350 related articles for article (PubMed ID: 18034952)
1. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.
Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Yedilbayev A; Rich ML; Mukherjee JS; Furin JJ; Atwood S; Farmer PE; Keshavjee S
Int J Tuberc Lung Dis; 2007 Dec; 11(12):1314-20. PubMed ID: 18034952
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.
Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Nikiforov M; Yedilbayev A; Mukherjee JS; Furin JJ; Barry DJ; Farmer PE; Rich ML; Keshavjee S
Int J Tuberc Lung Dis; 2006 Apr; 10(4):402-8. PubMed ID: 16602404
[TBL] [Abstract][Full Text] [Related]
3. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823
[TBL] [Abstract][Full Text] [Related]
4. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
[TBL] [Abstract][Full Text] [Related]
5. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis.
Furin JJ; Mitnick CD; Shin SS; Bayona J; Becerra MC; Singler JM; Alcantara F; Castañieda C; Sanchez E; Acha J; Farmer PE; Kim JY
Int J Tuberc Lung Dis; 2001 Jul; 5(7):648-55. PubMed ID: 11467371
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran.
Baghaei P; Tabarsi P; Dorriz D; Marjani M; Shamaei M; Pooramiri MV; Mansouri D; Farnia P; Masjedi M; Velayati A
Am J Ther; 2011; 18(2):e29-34. PubMed ID: 20019591
[TBL] [Abstract][Full Text] [Related]
8. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.
Anger HA; Dworkin F; Sharma S; Munsiff SS; Nilsen DM; Ahuja SD
J Antimicrob Chemother; 2010 Apr; 65(4):775-83. PubMed ID: 20150181
[TBL] [Abstract][Full Text] [Related]
9. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006.
Masjedi MR; Tabarsi P; Chitsaz E; Baghaei P; Mirsaeidi M; Amiri MV; Farnia P; Javanmard P; Mansouri D; Velayati AA
Int J Tuberc Lung Dis; 2008 Jul; 12(7):750-5. PubMed ID: 18544199
[TBL] [Abstract][Full Text] [Related]
10. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic.
Kim HJ; Hong YP; Kim SJ; Lew WJ; Lee EG
Int J Tuberc Lung Dis; 2001 Dec; 5(12):1129-36. PubMed ID: 11769771
[TBL] [Abstract][Full Text] [Related]
11. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
Park SK; Lee WC; Lee DH; Mitnick CD; Han L; Seung KJ
Int J Tuberc Lung Dis; 2004 Mar; 8(3):361-8. PubMed ID: 15139476
[TBL] [Abstract][Full Text] [Related]
12. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for multidrug-resistant tuberculosis in Hong Kong.
Law WS; Yew WW; Chiu Leung C; Kam KM; Tam CM; Chan CK; Leung CC
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1065-70. PubMed ID: 18713506
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus.
Ollé-Goig JE; Sandy R
Int J Tuberc Lung Dis; 2005 Jul; 9(7):765-70. PubMed ID: 16013772
[TBL] [Abstract][Full Text] [Related]
15. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002.
Shean KP; Willcox PA; Siwendu SN; Laserson KF; Gross L; Kammerer S; Wells CD; Holtz TH
Int J Tuberc Lung Dis; 2008 Oct; 12(10):1182-9. PubMed ID: 18812049
[TBL] [Abstract][Full Text] [Related]
17. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis.
Shin SS; Hyson AM; Castañeda C; Sánchez E; Alcántara F; Mitnick CD; Fawzi MC; Bayona J; Farmer PE; Kim JY; Furin JJ
Int J Tuberc Lung Dis; 2003 Apr; 7(4):347-53. PubMed ID: 12729340
[TBL] [Abstract][Full Text] [Related]
18. High levels of resistance to second-line anti-tuberculosis drugs among prisoners with pulmonary tuberculosis in Georgia.
Jugheli L; Rigouts L; Shamputa IC; Bram de Rijk W; Portaels F
Int J Tuberc Lung Dis; 2008 May; 12(5):561-6. PubMed ID: 18419893
[TBL] [Abstract][Full Text] [Related]
19. Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease.
Keshavjee S; Gelmanova IY; Pasechnikov AD; Mishustin SP; Andreev YG; Yedilbayev A; Furin JJ; Mukherjee JS; Rich ML; Nardell EA; Farmer PE; Kim JY; Shin SS
Ann N Y Acad Sci; 2008; 1136():1-11. PubMed ID: 17954675
[TBL] [Abstract][Full Text] [Related]
20. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs.
Codecasa LR; Ferrara G; Ferrarese M; Morandi MA; Penati V; Lacchini C; Vaccarino P; Migliori GB
Respir Med; 2006 Sep; 100(9):1566-72. PubMed ID: 16469488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
